Y Intercept Hong Kong Ltd Increases Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Y Intercept Hong Kong Ltd raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 148.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,019 shares of the company's stock after buying an additional 15,556 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Vaxcyte were worth $2,973,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company's stock valued at $2,453,000 after acquiring an additional 8,685 shares in the last quarter. Natixis Advisors LLC boosted its stake in Vaxcyte by 61.1% during the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company's stock valued at $2,594,000 after purchasing an additional 8,606 shares during the last quarter. Tri Locum Partners LP bought a new stake in shares of Vaxcyte in the 2nd quarter worth $8,559,000. Hsbc Holdings PLC purchased a new position in shares of Vaxcyte in the second quarter worth $1,053,000. Finally, Lisanti Capital Growth LLC lifted its holdings in shares of Vaxcyte by 68.1% during the third quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company's stock valued at $3,715,000 after purchasing an additional 13,175 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Stock Down 1.8 %

PCVX traded down $1.63 during trading on Tuesday, hitting $90.43. The company's stock had a trading volume of 951,907 shares, compared to its average volume of 905,805. Vaxcyte, Inc. has a one year low of $53.83 and a one year high of $121.06. The business's 50 day simple moving average is $103.01 and its 200-day simple moving average is $91.26. The firm has a market cap of $11.27 billion, a PE ratio of -19.66 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the company earned ($0.91) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on PCVX. Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Bank of America boosted their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. BTIG Research boosted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Finally, Mizuho increased their price target on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $147.50.

Insider Activity

In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,429,294.37. The trade was a 31.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mikhail Eydelman sold 5,000 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the sale, the senior vice president now owns 28,623 shares in the company, valued at $3,127,635.21. This represents a 14.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 117,830 shares of company stock valued at $12,600,310 in the last ninety days. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.